Syntara Limited · ASX:SNT
Syntara — Shareholder Meeting (November 2026)
17 slides from Syntara's shareholder meeting presentation, Nov 19, 2026
Slide 1: 2026 Annual General Meeting CEO Presentation
2026 Annual General Meeting CEO Presentation Gary Phillips, CEO 19th November 2026
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This document contains risks, uncertainties and other forward-looking statements, factors, many of which are including statements beyond our control, and which concerning Syntara’s future may cause actual results to financial position, plans, and the differ materially from
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Australian-founded Backed by Multiple shots on Funded into CY28 with near clinical stage specialist healthcare goal from additional term events to drive value drug developer investors – Phase 2, Phase 1 and over the next 12 months. 44% institutional preclinical assets (Sept 26;
Slide 4: Shareholders & Cash
SHAREHOLDERS & CASH Financial Information (ASX: SNT) Share Price & Volume - YTD Share price – 18th November 2026 $0.014 Close 0.04 Market cap A$27.5m Cash balance A$14.1m 0.03 Enterprise value A$13.4m 0.02 0.01 Institutional Ownership 30 Sep 26 0 D&A Income Limited 18% Volume Platinum Investment Man
Slide 5: Assets with Clinical Proof of Concept
ASSETS WITH CLINICAL PROOF OF CONCEPT A clinical-stage pipeline across blood cancers, fibrosis and neurodegenerative disease ASSET INDICATION TOTAL ADDRESSABLE MARKET DEVELOPMENT STATUS • Phase 2a clinical proof of concept in MF - complete Haematological Myelofibrosis: ~US$2.8b p.a. • FDA-aligned pl
Slide 6: Amsulostat: Lead Asset and a Key Driver of Value
• FDA IND and orphan drug designation in myelofibrosis • First and best in class pan-LOX inhibitor • Long patent life AMSULOSTAT: • Multiple Nature publications LEAD ASSET AND A KEY • Final Phase 2a trial data in combination with DRIVER OF VALUE ruxolitinib presented at ASH 2025 • Clearly differenti
Slide 7: Myelofibrosis
MYELOFIBROSIS A rare type of bone marrow cancer that disrupts the body’s normal production of blood cells KEY FACTS Myelofibrosis characterised by a build up of scar tissue • Orphan disease affects ~55k people in 7MM (fibrosis) in bone marrow and abnormal proliferation of (USA, Japan, 5EU); USA ~ 20
Slide 8: Myelofibrosis: Limited treatment options currently
MYELOFIBROSIS Limited treatment options currently Current standard of care (SoC): JAK inhibitors Amsulostat In contrast to SoC, amsulostat intervenes at the Key• Class Factsof drugs used in the management of splenomegaly source, inhibiting the family of lysyl oxidase (enlarged spleen) and other cons
Slide 9: Amsulostat Shows Competitive Efficacy
AMSULOSTAT SHOWS COMPETITIVE EFFICACY Comparison of open-label Phase 2 studies in suboptimal patient populations Phase 2 Open Label Trial Results in Suboptimal Patient Population Latest Program Drug Status Baseline Characteristics N TSS50 SVR25 SVR35 (median, range) Second P3 naïve MF 37% (30/81) 27
Slide 10: Strong Interest in MF Assets from Strategics
STRONG INTEREST IN MF ASSETS FROM STRATEGICS Target / Acquiror / / / / / DATE OF JULY-2026 APRIL-2026 MARCH-2026 DEC-2024 FEB-2024 ANNOUNCEMENT* Drug Name Navtemadlin AJ1-11095 Rovadicitinib Elritercept Pelabresib MDS and MF Myelofibrosis Lead Indication / Myelofibrosis Myelofibrosis Myelofibrosis (
Slide 11: BRIDGE-MF: Study Design
BRIDGE-MF: STUDY DESIGN Study designed to strengthen confidence in both efficacy and disease-modifying relevance Trial Design amsulostat Timeline of Main Cohort A 200 mg BID Activities + • Patients with MF on ruxolitinib for min 3 months Preparation Phase ruxolitinib BID • Current inadequate respons
Slide 12: SNT-4728 for Neuroinflammation: Brief History
SNT-4728: BRIEF HISTORY SNT-4728 FOR NEUROINFLAMMATION Safe and efficacious, small molecule enzyme inhibitor that crosses the blood brain barrier A novel approach • Syntara discovered and wholly • Strong preclinical and clinical owned asset data support the role of SSAO • Drug extensively de-risked
Slide 13: iRBD and Parkinson's
iRBD AND PARKINSON’S Using a sleep disorder to target Parkinson’s. KEY FACTS Early intervention to demonstrate neuroprotection – rather than late treatment when most neurons have already been • Patients with isolated REM sleep behaviour lost (for example in PD) – is where disease-modifying, disorder
Slide 14: Reduction in Inflammation
REDUCTION IN Binding Potential (BPND) P-value INFLAMMATION Putamen Mean at Mean at Mean change (Paired t- test) baseline 12 weeks Statistically significant Right 0.002918 -0.012073 -0.016 (0.033) 0.0145 reduction in brain inflammation observed unilaterally in the Left -0.001209 0.001692 0.003 (0.029
Slide 15: Clinical Measures
CLINICAL MEASURES MDS-UPDRS Part III Total Score 10 SNT-4728, n=30 Significant difference between Placebo, n=11 SNT-4728 and placebo in motor p=0.021 signs Mean Change, 95% CI p=0.183 5 MDS-UPDRS • Small decrease over time (even after treatment cessation) in the Part III total score within the SNT-4
Slide 16: The Year Ahead - Poised to Deliver Near Term Value
THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE TARGET DRUG INDICATION PARTNERS PHASE 1 PHASE 2 ANTICIPATED NEWS FLOW HEALTHY H2 2026 H1 2027 PATIENTS PARTICIPANTS FDA approved Partner development plan engagement & Myelofibrosis and partner trial funding engagement discussions Interim safety and
Slide 17: Gary Phillips, Chief Executive Officer
Gary Phillips Chief Executive Officer gary.phillips@syntaratx.com.au http://syntaratx.com.au